These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 22110952)

  • 1. Proteomic-based biosignatures in breast cancer classification and prediction of therapeutic response.
    He J; Whelan SA; Lu M; Shen D; Chung DU; Saxton RE; Faull KF; Whitelegge JP; Chang HR
    Int J Proteomics; 2011; 2011():896476. PubMed ID: 22110952
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular Subtyping of Triple-Negative Breast Cancers by Immunohistochemistry: Molecular Basis and Clinical Relevance.
    Zhao S; Ma D; Xiao Y; Li XM; Ma JL; Zhang H; Xu XL; Lv H; Jiang WH; Yang WT; Jiang YZ; Zhang QY; Shao ZM
    Oncologist; 2020 Oct; 25(10):e1481-e1491. PubMed ID: 32406563
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hydrophobic Proteome Analysis of Triple Negative and Hormone-Receptor-Positive-Her2-Negative Breast Cancer by Mass Spectrometer.
    Lu M; Whelan SA; He J; Saxton RE; Faull KF; Whitelegge JP; Chang HR
    Clin Proteomics; 2010 Sep; 6(3):93-103. PubMed ID: 20930921
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer.
    Ono M; Tsuda H; Shimizu C; Yamamoto S; Shibata T; Yamamoto H; Hirata T; Yonemori K; Ando M; Tamura K; Katsumata N; Kinoshita T; Takiguchi Y; Tanzawa H; Fujiwara Y
    Breast Cancer Res Treat; 2012 Apr; 132(3):793-805. PubMed ID: 21562709
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential response of triple-negative breast cancer to a docetaxel and carboplatin-based neoadjuvant treatment.
    Chang HR; Glaspy J; Allison MA; Kass FC; Elashoff R; Chung DU; Gornbein J
    Cancer; 2010 Sep; 116(18):4227-37. PubMed ID: 20549829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single-cell atlas reveals a distinct immune profile fostered by T cell-B cell crosstalk in triple negative breast cancer.
    Ding S; Qiao N; Zhu Q; Tong Y; Wang S; Chen X; Tian Q; Xiao Y; Shen K
    Cancer Commun (Lond); 2023 Jun; 43(6):661-684. PubMed ID: 37158690
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proteomic profiling of triple-negative breast carcinomas in combination with a three-tier orthogonal technology approach identifies Mage-A4 as potential therapeutic target in estrogen receptor negative breast cancer.
    Cabezón T; Gromova I; Gromov P; Serizawa R; Timmermans Wielenga V; Kroman N; Celis JE; Moreira JM
    Mol Cell Proteomics; 2013 Feb; 12(2):381-94. PubMed ID: 23172894
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genomic insights into triple-negative and HER2-positive breast cancers using isogenic model systems.
    Mudvari P; Ohshiro K; Nair V; Horvath A; Kumar R
    PLoS One; 2013; 8(9):e74993. PubMed ID: 24086418
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery and Pharmacological Evaluation of STEAP4 as a Novel Target for HER2 Overexpressing Breast Cancer.
    Orfanou IM; Argyros O; Papapetropoulos A; Tseleni-Balafouta S; Vougas K; Tamvakopoulos C
    Front Oncol; 2021; 11():608201. PubMed ID: 33842315
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative proteomic profiling of triple-negative breast cancer reveals that up-regulation of RhoGDI-2 is associated to the inhibition of caspase 3 and caspase 9.
    Muñiz Lino MA; Palacios-Rodríguez Y; Rodríguez-Cuevas S; Bautista-Piña V; Marchat LA; Ruíz-García E; Astudillo-de la Vega H; González-Santiago AE; Flores-Pérez A; Díaz-Chávez J; Carlos-Reyes Á; Álvarez-Sánchez E; López-Camarillo C
    J Proteomics; 2014 Dec; 111():198-211. PubMed ID: 24768906
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The TRAIL receptor agonist drozitumab targets basal B triple-negative breast cancer cells that express vimentin and Axl.
    Dine JL; O'Sullivan CC; Voeller D; Greer YE; Chavez KJ; Conway CM; Sinclair S; Stone B; Amiri-Kordestani L; Merchant AS; Hewitt SM; Steinberg SM; Swain SM; Lipkowitz S
    Breast Cancer Res Treat; 2016 Jan; 155(2):235-51. PubMed ID: 26759246
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Triple-negative breast cancer and basal-like subtype : Pathology and targeted therapy.
    Bando Y; Kobayashi T; Miyakami Y; Sumida S; Kakimoto T; Saijo Y; Uehara H
    J Med Invest; 2021; 68(3.4):213-219. PubMed ID: 34759133
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy.
    Darb-Esfahani S; Denkert C; Stenzinger A; Salat C; Sinn B; Schem C; Endris V; Klare P; Schmitt W; Blohmer JU; Weichert W; Möbs M; Tesch H; Kümmel S; Sinn P; Jackisch C; Dietel M; Reimer T; Loi S; Untch M; von Minckwitz G; Nekljudova V; Loibl S
    Oncotarget; 2016 Oct; 7(42):67686-67698. PubMed ID: 27611952
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Accuracy of morphologic change measurements by ultrasound in predicting pathological response to neoadjuvant chemotherapy in triple-negative and HER2-positive breast cancer.
    Ochi T; Tsunoda H; Matsuda N; Nozaki F; Suzuki K; Takei H; Yamauchi H
    Breast Cancer; 2021 Jul; 28(4):838-847. PubMed ID: 33560514
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Role and Mechanism of CRT0066101 as an Effective Drug for Treatment of Triple-Negative Breast Cancer.
    Liu Y; Wang Y; Yu S; Zhou Y; Ma X; Su Q; An L; Wang F; Shi A; Zhang J; Chen L
    Cell Physiol Biochem; 2019; 52(3):382-396. PubMed ID: 30845378
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of SIRT1, SIRT3 and SIRT6 Genes for Predicting Survival in Triple-Negative and Hormone Receptor-Positive Subtypes of Breast Cancer.
    Uzelac B; Krivokuca A; Brankovic-Magic M; Magic Z; Susnjar S; Milovanovic Z; Supic G
    Pathol Oncol Res; 2020 Oct; 26(4):2723-2731. PubMed ID: 32681437
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Clinicopathological Analysis of Molecular Subtypes of Breast Cancer using Immunohistochemical Surrogates: A 6-Year Institutional Experience from a Tertiary Cancer Center in North India.
    Somal PK; Sancheti S; Sharma A; Sali AP; Chaudhary D; Goel A; Dora TK; Brar R; Gulia A; Divatia J
    South Asian J Cancer; 2023 Apr; 12(2):104-111. PubMed ID: 37969672
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Construction and validation of a gene expression classifier to predict immunotherapy response in primary triple-negative breast cancer.
    Ensenyat-Mendez M; Orozco JIJ; Llinàs-Arias P; Íñiguez-Muñoz S; Baker JL; Salomon MP; Martí M; DiNome ML; Cortés J; Marzese DM
    Commun Med (Lond); 2023 Jul; 3(1):93. PubMed ID: 37430006
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of predictive and prognostic value of androgen receptor expression in breast cancer subtypes treated with neoadjuvant chemotherapy.
    Shi Z; Liu Y; Zhang S; Cai S; Liu X; Meng J; Zhang J
    Discov Oncol; 2023 Apr; 14(1):49. PubMed ID: 37099044
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current Triple-Negative Breast Cancer Subtypes: Dissecting the Most Aggressive Form of Breast Cancer.
    Ensenyat-Mendez M; Llinàs-Arias P; Orozco JIJ; Íñiguez-Muñoz S; Salomon MP; Sesé B; DiNome ML; Marzese DM
    Front Oncol; 2021; 11():681476. PubMed ID: 34221999
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.